Stoke Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €220.03M +170.7% €5.15M -104.8% 2.3% +1.3 pp €97.07M -321.0% 44.1% +0.98 pp
    (estimated) €81.28M +63.6% -€107.11M -27.8% -131.8% +1.7 pp -€43.93M -65.3% -54.0% +2.0 pp
    (estimated) €49.69M +121.4% -€148.29M -1.6% -298.4% +3.7 pp -€126.58M +43.2% -254.7% +1.4 pp
    (estimated) €22.45M -85.8% -€150.66M -1,293.4% -671.1% -6.8 pp -€88.41M -319.1% -393.8% -4.2 pp
    (estimated) €158.27M +407.6% €12.62M -116.6% 8.0% +2.5 pp €40.34M -154.6% 25.5% +2.6 pp
    €31.18M +316.3% -€75.90M -15.0% -243.4% +9.5 pp -€73.91M +9.1% -237.0% +6.7 pp
    €7.49M -29.2% -€89.30M +12.4% -1,192.5% -4.4 pp -€67.77M +184.7% -904.9% -6.8 pp
    €10.58M +∞% -€79.42M +9.9% -750.6% -7.5 pp -€23.80M -57.5% -224.9% -2.2 pp
    €0.00 +NaN% -€72.25M +67.4% N/A -€56.04M +59.6% N/A
    €0.00 +NaN% -€43.17M +77.4% N/A -€35.12M +39.9% N/A
    €0.00 +NaN% -€24.33M +127.8% N/A -€25.09M +193.3% N/A
    €0.00 +NaN% -€10.68M +125.3% N/A -€8.55M +90.3% N/A
    €0.00 -€4.74M N/A -€4.50M N/A

    Notifications